Cargando…

Different Effects of Empagliflozin on Markers of Mineral-Bone Metabolism in Diabetic and Non-Diabetic Patients with Stage 3 Chronic Kidney Disease

Background and objectives: Treatment with sodium–glucose co-transporter 2 (SGLT2) inhibitors decrease tubular reabsorption of phosphate, which may explain the reduction of bone mineral density and an excess of bone fractures observed in some studies with this class of drugs. Since an increased risk...

Descripción completa

Detalles Bibliográficos
Autores principales:	Masajtis-Zagajewska, Anna, Hołub, Tomasz, Pęczek, Katarzyna, Makówka, Agnieszka, Nowicki, Michał
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705759/ https://www.ncbi.nlm.nih.gov/pubmed/34946298 http://dx.doi.org/10.3390/medicina57121352

Ejemplares similares

Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease – a randomized double blind crossover study
por: Masajtis-Zagajewska, Anna, et al.
Publicado: (2018)

Effects of a Structured Physical Activity Program on Serum Adipokines and Markers of Inflammation and Volume Overload in Kidney Transplant Recipients
por: Muras-Szwedziak, Katarzyna, et al.
Publicado: (2019)

Secondary Hemophagocytic Lymphohistiocytosis Complicated by a Cavitary Lung Lesion in a Kidney Transplant Recipient
por: Muras-Szwedziak, Katarzyna, et al.
Publicado: (2021)

Utility of copeptin and standard inflammatory markers in the diagnostics of upper and lower urinary tract infections
por: Masajtis-Zagajewska, Anna, et al.
Publicado: (2015)

Losartan and Eprosartan Induce a Similar Effect on the Acute Rise in Serum Uric Acid Concentration after an Oral Fructose Load in Patients with Metabolic Syndrome
por: Masajtis-Zagajewska, Anna, et al.
Publicado: (2021)

Novel Complement Factor B Gene Mutation Identified in a Kidney Transplant Recipient with a Shiga Toxin-Triggered Episode of Thrombotic Microangiopathy
por: Korzycka, Joanna, et al.
Publicado: (2022)

Effects of combined statin and ACE inhibitor therapy on endothelial function and blood pressure in essential hypertension - a randomised double-blind, placebo controlled crossover study
por: Ruszkowski, Piotr, et al.
Publicado: (2019)

‘I hear and I forget. I see and I remember. I do and I understand.’– incorporating high-fidelity medical simulation into the undergraduate nephrology course
por: Pawłowicz, Ewa, et al.
Publicado: (2020)

Different Effect of Lanthanum Carbonate and Sevelamer Hydrochloride on Calcium Balance in Patients with Moderate to Advanced Chronic Kidney Disease
por: Makowka, Agnieszka, et al.
Publicado: (2021)

Impact of empagliflozin on diabetic kidney disease
por: Koya, Daisuke
Publicado: (2017)

Dietary Phosphorus as a Marker of Mineral Metabolism and Progression of Diabetic Kidney Disease
por: Winiarska, Agata, et al.
Publicado: (2021)

Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease
por: Hojná, Silvie, et al.
Publicado: (2022)

Mineral and bone metabolism markers and mortality in diabetic patients on haemodialysis
por: Martín-Carro, Beatriz, et al.
Publicado: (2023)

Emphysematous Kidney Related to the Use of Empagliflozin in a Diabetic Woman
por: Echeverria, Pablo, et al.
Publicado: (2023)

Empagliflozin in type 1 diabetes
por: Mathieu, Chantal, et al.
Publicado: (2019)

Effects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes
por: Reppo, Ingrid, et al.
Publicado: (2023)

Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats
por: Kuno, Atsushi, et al.
Publicado: (2020)

Treatment of chronic hemodialysis patients with low-dose fenofibrate effectively reduces plasma lipids and affects plasma redox status
por: Makówka, Agnieszka, et al.
Publicado: (2012)

Initial Combination Empagliflozin and Linagliptin Improves Kidney Fibrotic Marker in Patients With Type 2 Diabetes: A Randomized Controlled Trial
por: Sathavarodom, Nattapol, et al.
Publicado: (2021)

Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK)
por: Domon, Ayaka, et al.
Publicado: (2021)

Empagliflozin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2020)

Empagliflozin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2022)

Empagliflozin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

Empagliflozin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus
por: Albugami, Muneerah M., et al.
Publicado: (2020)

Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats
por: Trang, Nguyen Ngoc, et al.
Publicado: (2021)

Empagliflozin Contributes to Polyuria via Regulation of Sodium Transporters and Water Channels in Diabetic Rat Kidneys
por: Chung, Sungjin, et al.
Publicado: (2019)

Empagliflozin in the treatment of type 2 diabetes: evidence to date
por: Shubrook, Jay H, et al.
Publicado: (2015)

Myopathy secondary to empagliflozin therapy in type 2 diabetes
por: Gao, Frank, et al.
Publicado: (2020)

Empagliflozin: Euglycemic and hyperglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

Empagliflozin: Euglycaemic diabetic ketoacidosis: 2 case reports
Publicado: (2021)

Empagliflozin/linagliptin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

Effect of Empagliflozin on Sphingolipid Catabolism in Diabetic and Hypertensive Rats
por: Pérez-Villavicencio, Roxana, et al.
Publicado: (2022)

Empagliflozin in Patients with Chronic Kidney Disease
por: Herrington, William G., et al.
Publicado: (2023)

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
por: Chilton, R., et al.
Publicado: (2015)

Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis
por: Ray, Gretchen M., et al.
Publicado: (2019)

Changes of Serum Bone Metabolism Indexes and Ultrasonic Bone Mineral Density in Patients with Diabetic Nephropathy at Different Stages and their effects on Diabetic Renal Microvascular Complications
por: Han, Lulu, et al.
Publicado: (2023)

Markers of Glomerular and Tubular Damage in the Early Stage of Kidney Disease in Type 2 Diabetic Patients
por: Żyłka, Agnieszka, et al.
Publicado: (2018)

Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure
por: Thiele, Kirsten, et al.
Publicado: (2022)

Organizational support, training and equipment are key determinants of burnout among dialysis healthcare professionals during the COVID-19 pandemic
por: Pawłowicz-Szlarska, Ewa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nta0p5tosqep7amg2s29pgdlm4